{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:33:51Z","timestamp":1792596831803,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Symptomatic treatment for Alzheimer's disease (AD) dementia could temporarily slow symptom worsening and improve the quality of life for both AD dementia patients and their caregivers. A comprehensive evaluation of symptomatic treatment patterns using recent data for newly diagnosed AD dementia has not been performed and compared across different countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The drug name, time to the first therapy, duration, discontinuation or switches were described in newly diagnosed AD dementia patients in two databases (a major U.S. health plan [US] and UK-Clinical Practice Research Datalink [CPRD GOLD]). This analysis included patients with newly diagnosed AD dementia in 2018\u20132019, who initiated symptomatic AD drug therapy, with\u2009\u2265\u20091 year baseline period and\u2009\u2265\u20091 year of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over median follow-ups of 698 and 645 days, 63% and 65% of AD dementia patients used symptomatic treatments, with 34% and 77% newly initiating therapy, constituting analytic samples of 7637 patients in the US database and 4470 patients in the CPRD, respectively. The median time to the first therapy was 14 days for US and 49 days for CPRD; donepezil ranked the as most frequently used (69% vs 61%), followed by memantine (19% vs 28%) in the US\u00a0database and CPRD, respectively. Median time on first therapy was 213 and 334 days, and 30% and 12% of patients proceeded to a second treatment in the US and CPRD databases, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Approximately two thirds of newly diagnosed AD dementia patients utilized approved symptomatic treatment. Time on first therapy was relatively short (&lt;\u20091 year) and the majority did not move to a second therapy, highlighting the need for better adherence and persistence to existing AD symptomatic therapies and the need for additional therapies to alleviate the significant burden of AD dementia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-023-03447-5","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T03:30:48Z","timestamp":1699500648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD)"],"prefix":"10.1186","volume":"23","author":[{"given":"Julia R.","family":"DiBello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Bortnichak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Li","family":"Liaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"3447_CR1","doi-asserted-by":"publisher","unstructured":"2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19:1598\u2013695. https:\/\/doi.org\/10.1002\/alz.13016. Epub 2023 Mar 14.","DOI":"10.1002\/alz.13016"},{"issue":"1","key":"3447_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jalz.2018.06.3063","volume":"15","author":"KA Matthews","year":"2019","unstructured":"Matthews KA, et al. Racial and ethnic estimates of Alzheimer\u2019s disease and related dementias in the United States (2015\u20132060) in adults aged \u226565 years. Alzheimers Dement. 2019;15(1):17\u201324. https:\/\/doi.org\/10.1016\/j.jalz.2018.06.3063.","journal-title":"Alzheimers Dement."},{"issue":"7","key":"3447_CR3","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","volume":"15","author":"L Vermunt","year":"2019","unstructured":"Vermunt L, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15(7):888\u201398.","journal-title":"Alzheimers Dement."},{"key":"3447_CR4","first-page":"393","volume":"2020","author":"R Duan","year":"2021","unstructured":"Duan R, et al. Leverage real-world longitudinal data in large clinical research networks for Alzheimer\u2019s Disease and Related Dementia (ADRD). AMIA Annu Symp Proc. 2021;2020:393\u2013401.","journal-title":"AMIA Annu Symp Proc."},{"issue":"8","key":"3447_CR5","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/aje\/kwac063","volume":"191","author":"MM Glymour","year":"2022","unstructured":"Glymour MM, et al. Aduhelm, the newly approved medication for Alzheimer disease: what epidemiologists can learn and what epidemiology can offer. Am J Epidemiol. 2022;191(8):1347\u201351.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"3447_CR6","first-page":"362","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"key":"3447_CR7","doi-asserted-by":"publisher","first-page":"117957352090739","DOI":"10.1177\/1179573520907397","volume":"12","author":"KG Yiannopoulou","year":"2020","unstructured":"Yiannopoulou KG, Papageorgiou SG. Current and Future Treatments in Alzheimer Disease: An Update. J Cent Nerv Syst Dis. 2020;12:1179573520907397.","journal-title":"J Cent Nerv Syst Dis."},{"issue":"2","key":"3447_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1213\/00000539-199608000-00020","volume":"83","author":"G Scheiber","year":"1996","unstructured":"Scheiber G, et al. Intubating conditions and onset of action after rocuronium, vecuronium, and atracurium in young children. Anesth Analg. 1996;83(2):320\u20134.","journal-title":"Anesth Analg"},{"key":"3447_CR9","unstructured":"World Health Organization.\u00a0https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia. Accessed 8\u00a0May 2020."},{"issue":"1","key":"3447_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/jgs.15069","volume":"66","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, et al. Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer\u2019s disease: systematic review and network metaanalysis. J Am Geriatr Soc. 2018;66(1):170\u20138.","journal-title":"J Am Geriatr Soc."},{"issue":"2","key":"3447_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0039-1678581","volume":"39","author":"A Atri","year":"2019","unstructured":"Atri A. Current and future treatments in Alzheimer\u2019s disease. Semin Neurol. 2019;39(2):227\u201340.","journal-title":"Semin Neurol."},{"issue":"2","key":"3447_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3233\/JAD-200133","volume":"76","author":"D Barthold","year":"2020","unstructured":"Barthold D, et al. Pharmaceutical treatment for alzheimer\u2019s disease and related dementias: utilization and disparities. J Alzheimers Dis. 2020;76(2):579\u201389.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"3447_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40120-017-0067-7","volume":"6","author":"N Bent-Ennakhil","year":"2017","unstructured":"Bent-Ennakhil N, et al. A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer\u2019s disease patients. Neurol Ther. 2017;6(1):131\u201344.","journal-title":"Neurol Ther"},{"issue":"3","key":"3447_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00127-020-01872-2","volume":"56","author":"G James","year":"2021","unstructured":"James G, et al. Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe. Soc Psychiatry Psychiatr Epidemiol. 2021;56(3):409\u201316.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"1","key":"3447_CR15","doi-asserted-by":"publisher","first-page":"e12014","DOI":"10.1002\/trc2.12014","volume":"6","author":"R Wurm","year":"2020","unstructured":"Wurm R, et al. Prescription patterns of antidementives in a high income country: a pharmacoepidemiologic study. Alzheimers Dement (N Y). 2020;6(1).","journal-title":"Alzheimers Dement (N Y)"},{"key":"3447_CR16","unstructured":"Rabins PV, Blacker D, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer\u2019s disease and other dementias. Second edition. Am J Psychiatry. 2007;164(12 Suppl):5\u201356."},{"issue":"11","key":"3447_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1177\/1755738020910775","volume":"14","author":"C Bird","year":"2020","unstructured":"Bird C, et al. NICE Nuggets: NG97: Dementia: Assessment, management and support for people living with dementia and their carers and QS184: Dementia. InnovAiT. 2020;14(11):706\u20138.","journal-title":"InnovAiT"},{"key":"3447_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jclinane.2016.04.033","volume":"33","author":"M Azizoglu","year":"2016","unstructured":"Azizoglu M, et al. Reversal of profound neuromuscular blockade with sugammadex in an infant after bronchial foreign body removal. J Clin Anesth. 2016;33:315\u20136.","journal-title":"J Clin Anesth"},{"issue":"3","key":"3447_CR19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827\u201336.","journal-title":"Int J Epidemiol"},{"key":"3447_CR20","doi-asserted-by":"publisher","first-page":"749305","DOI":"10.3389\/fnins.2021.749305","volume":"15","author":"LM Butler","year":"2021","unstructured":"Butler LM, et al. Comorbidity trajectories associated with Alzheimer\u2019s disease: a matched case-control study in a United States claims database. Front Neurosci. 2021;15.","journal-title":"Front Neurosci"},{"issue":"6","key":"3447_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jalz.2012.09.015","volume":"9","author":"CW Zhu","year":"2013","unstructured":"Zhu CW, et al. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer\u2019s disease. Alzheimers Dement. 2013;9(6):733\u201340.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"3447_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/147323000603400401","volume":"34","author":"B Seltzer","year":"2006","unstructured":"Seltzer B. Cholinesterase inhibitors in the clinical management of Alzheimer\u2019s disease: importance of early and persistent treatment. J Int Med Res. 2006;34(4):339\u201347.","journal-title":"J Int Med Res"},{"issue":"7","key":"3447_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40266-015-0273-x","volume":"32","author":"WJ Deardorff","year":"2015","unstructured":"Deardorff WJ, Feen E, Grossberg GT. The use of cholinesterase inhibitors across all stages of Alzheimer\u2019s disease. Drugs Aging. 2015;32(7):537\u201347.","journal-title":"Drugs Aging"},{"key":"3447_CR24","unstructured":"Effects of Alzheimer's disease drugs.\u00a0https:\/\/www.alzheimers.org.uk\/about-dementia\/treatments\/drugs\/effects-of-alzheimers-drugs#content-start.\u00a0 Accessed\u00a010 Oct\u00a0 2023."},{"issue":"3","key":"3447_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1185\/030079902125000471","volume":"18","author":"S Auriacombe","year":"2002","unstructured":"Auriacombe S, et al. Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002;18(3):129\u201338.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"3447_CR26","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/gps.4985","volume":"33","author":"RH Lim","year":"2018","unstructured":"Lim RH, Sharmeen T. Medicines management issues in dementia and coping strategies used by people living with dementia and family carers: a systematic review. Int J Geriatr Psychiatry. 2018;33(12):1562\u201381.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"5","key":"3447_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/ageing\/afz045","volume":"48","author":"R McCabe","year":"2019","unstructured":"McCabe R, et al. Patient and companion shared decision making and satisfaction with decisions about starting cholinesterase medication at dementia diagnosis. Age Ageing. 2019;48(5):711\u20138.","journal-title":"Age Ageing"},{"issue":"5","key":"3447_CR28","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1177\/1471301214555542","volume":"15","author":"LM Miller","year":"2016","unstructured":"Miller LM, Whitlatch CJ, Lyons KS. Shared decision-making in dementia: a review of patient and family carer involvement. Dementia. 2016;15(5):1141\u201357.","journal-title":"Dementia"},{"issue":"5","key":"3447_CR29","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s11606-020-06442-5","volume":"36","author":"MJ Sawan","year":"2021","unstructured":"Sawan MJ, et al. Interventions at hospital discharge to guide caregivers in medication management for people living with dementia: a systematic review. J Gen Intern Med. 2021;36(5):1371\u20139.","journal-title":"J Gen Intern Med"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03447-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03447-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03447-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T03:30:53Z","timestamp":1699500653000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03447-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3447"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03447-5","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"14 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain clinical studies or patient data. All the data utilized in this study were anonymized and are only reported in aggregate level. The use of CPRD data for research purposes received ethical approval by an Independent Scientific Advisory Research Data Governance Process for Medicines and Healthcare products Regulatory Agency (RDG-MHRA, application #21_000439). Approval from an NHS Research Ethics Committee (REC) was not required as the study was purely observational. As this was a non-interventional study using anonymized data, no patient consent was necessary. This study was carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors except Jina Swarts are current employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and may hold stocks of Merck & Co., Inc., Rahway, NJ, USA. Yifei\u00a0Lu was affiliated with University of North Carolina at Chapel Hill at the time of the study.\u00a0Jina Swartz was a former\u00a0employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and may hold stocks of Merck & Co., Inc., Rahway, NJ, USA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"400"}}